The Rising Risk of Skin Cancer
Skin cancer is now the most common cancer globally, with over 5 million cases diagnosed annually in the United States alone. One in five Americans will develop skin cancer by the age of 70, and melanoma—the most dangerous form—kills more than 20 people daily in the U.S. Fortunately, early detection can make all the difference: melanoma’s 5-year survival rate jumps to over 99% when caught early. At LMI, we are committed to proactive detection and early intervention. Dr. Ross performs comprehensive full-body skin checks, identifying suspicious moles or lesions and monitoring them over time.
We are proud to offer DermaSensor™, the first FDA-cleared AI-powered handheld device for non-invasive skin cancer detection. This cutting-edge tool assesses lesions in under a minute, providing real-time, objective results right at the point of care. Using a technique called Elastic Scattering Spectroscopy (ESS), DermaSensor™ analyzes how light reflects off cellular structures within the skin. It then compares this light pattern to a vast database of known benign and malignant lesions, helping our dermatology team assess the likelihood of melanoma, basal cell carcinoma, or squamous cell carcinoma—on the spot. Studies show DermaSensor has a sensitivity rate exceeding 90%, meaning it’s highly accurate at identifying suspicious lesions. Advanced Skin Cancer Detection with DermaSensor™
Longevity Medical Institute (C) Copyright. All Rights Reserved.
02
Made with FlippingBook interactive PDF creator